JP2010500005A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500005A5
JP2010500005A5 JP2009506826A JP2009506826A JP2010500005A5 JP 2010500005 A5 JP2010500005 A5 JP 2010500005A5 JP 2009506826 A JP2009506826 A JP 2009506826A JP 2009506826 A JP2009506826 A JP 2009506826A JP 2010500005 A5 JP2010500005 A5 JP 2010500005A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009506826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500005A (ja
JP5244785B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2007/065991 external-priority patent/WO2008018641A1/en
Publication of JP2010500005A publication Critical patent/JP2010500005A/ja
Publication of JP2010500005A5 publication Critical patent/JP2010500005A5/ja
Application granted granted Critical
Publication of JP5244785B2 publication Critical patent/JP5244785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009506826A 2006-08-11 2007-08-10 ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体 Expired - Fee Related JP5244785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83700406P 2006-08-11 2006-08-11
US60/837,004 2006-08-11
PCT/JP2007/065991 WO2008018641A1 (en) 2006-08-11 2007-08-10 Monoclonal antibodies against stromal derived factor-1 (sdf-1)

Publications (3)

Publication Number Publication Date
JP2010500005A JP2010500005A (ja) 2010-01-07
JP2010500005A5 true JP2010500005A5 (cg-RX-API-DMAC7.html) 2010-08-19
JP5244785B2 JP5244785B2 (ja) 2013-07-24

Family

ID=39033152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009506826A Expired - Fee Related JP5244785B2 (ja) 2006-08-11 2007-08-10 ストローマ由来因子−1(sdf−1)に対するモノクローナル抗体

Country Status (6)

Country Link
US (1) US8496931B2 (cg-RX-API-DMAC7.html)
EP (1) EP2046834B9 (cg-RX-API-DMAC7.html)
JP (1) JP5244785B2 (cg-RX-API-DMAC7.html)
ES (1) ES2396220T3 (cg-RX-API-DMAC7.html)
TW (1) TW200817437A (cg-RX-API-DMAC7.html)
WO (1) WO2008018641A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021263A2 (en) * 2006-08-11 2008-02-21 Medarex, Inc. Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof
BRPI0911513A2 (pt) 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
CN102076350A (zh) 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 将骨髓来源的多能干细胞动员到末梢循环的药物
CN104825491A (zh) 2009-10-28 2015-08-12 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
US9308277B2 (en) * 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
ES2678497T3 (es) * 2010-09-09 2018-08-13 Noxxon Pharma Ag Ácidos nucleicos que se unen a SDF-1 y su uso en el tratamiento del cáncer
JP5843189B2 (ja) * 2011-03-15 2016-01-13 国立大学法人名古屋大学 Sdf−1阻害剤を含有した軟骨組織再生用組成物
CN107188948B (zh) 2011-04-26 2021-11-30 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
AU2012268078B2 (en) 2011-06-07 2017-06-01 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
CA2889275C (en) 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
WO2015019284A2 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
US10647766B2 (en) 2014-12-17 2020-05-12 Cancer Research Technology Limited Anti-CXCL12 antibody molecules and their uses
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
BR112019023138A2 (pt) 2017-05-05 2020-07-28 Vaccinex, Inc. anticorpo 4d anti-semaforina humano
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
KR102562168B1 (ko) * 2021-12-27 2023-08-02 주식회사 에피바이오텍 Cxcl12에 대한 항체 및 이를 포함하는 탈모 치료용 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003224712A1 (en) 2002-03-21 2003-10-08 University Of Florida Modulating angiogenesis
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2008021263A2 (en) 2006-08-11 2008-02-21 Medarex, Inc. Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof

Similar Documents

Publication Publication Date Title
JP2010500005A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2020023523A5 (cg-RX-API-DMAC7.html)
JP2008508864A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2018512138A5 (cg-RX-API-DMAC7.html)
JP2022065063A5 (cg-RX-API-DMAC7.html)
RU2019102393A (ru) Гуманизированные антитела к фактору d и их применения
JP2012501669A5 (cg-RX-API-DMAC7.html)
JP2019162105A5 (cg-RX-API-DMAC7.html)
JP2014039548A5 (cg-RX-API-DMAC7.html)
JP2011506422A5 (cg-RX-API-DMAC7.html)
JP2012501670A5 (cg-RX-API-DMAC7.html)
JP2016529882A5 (cg-RX-API-DMAC7.html)
TW201031421A (en) IL-1 binding proteins
CN106573053B (zh) 干扰素α和ω抗体拮抗剂
JP2007514419A5 (cg-RX-API-DMAC7.html)
JP2010229134A5 (cg-RX-API-DMAC7.html)
JP2020501583A5 (cg-RX-API-DMAC7.html)
JP2009532336A5 (cg-RX-API-DMAC7.html)
JP2015508757A5 (cg-RX-API-DMAC7.html)
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2011520898A5 (cg-RX-API-DMAC7.html)
JP2018502060A5 (cg-RX-API-DMAC7.html)
JP2008516970A5 (cg-RX-API-DMAC7.html)